Kauffman Michael — SEC Form 4 filings
SEC reporting owner CIK 1364719. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-17.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-03-13 to 2026-06-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 14,450 shares, $93,937 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: sale of 8,550 shares @ $10.00 ($85,500) in Verastem, Inc., filed 2025-11-25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Verastem, Inc. (VSTM) | President of Development, Director | 5 | — | 1 leg · 8,550 sh · $85,500 | 14 |
| Adicet Bio, Inc. (ACET) | Director | 2 | — | 1 leg · 5,900 sh · $8,437 | 8 |
| Kezar Life Sciences, Inc. (KZR) | Director | 3 | — | — | 11 |
| KYNTRA BIO, INC. (KYNB) | Director | 2 | — | — | 3 |
Form 4 filings — Kauffman Michael
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-17 | 4 | KYNTRA BIO, INC. (KYNB) | Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Kezar Life Sciences, Inc. (KZR) | Code (U): 6,369 · Disposition to issuer (D): 389 (derivative) @ $0 · Disposition to issuer (D): 3,500 (derivative) @ $0 · Disposition to issuer (D): 5,000 (derivative) @ $0 · Disposition to issuer (D): 5,000 (derivative) @ $0 · Disposition to issuer (D): 889 (derivative) @ $0 · +3 more | EDGAR |
| 2026-01-08 | 4 | Verastem, Inc. (VSTM) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Verastem, Inc. (VSTM) | Sale (S): 8,550 @ $10 | EDGAR |
| 2025-06-23 | 4 | Kezar Life Sciences, Inc. (KZR) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | FIBROGEN INC (FGEN) | Grant/award (A): 70,000 (derivative) @ $0 · Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | Verastem, Inc. (VSTM) | Grant/award (A): 8,333 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-08-23 | 4 | Adicet Bio, Inc. (ACET) | Disposition to issuer (D): 37,000 (derivative) @ $0 · Grant/award (A): 37,000 (derivative) @ $0 · Disposition to issuer (D): 18,500 (derivative) @ $0 · Grant/award (A): 18,500 (derivative) @ $0 · Disposition to issuer (D): 26,400 (derivative) @ $0 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Kezar Life Sciences, Inc. (KZR) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Verastem, Inc. (VSTM) | Grant/award (A): 8,333 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Adicet Bio, Inc. (ACET) | Grant/award (A): 5,900 @ $0 · Sale (S): 5,900 @ $1.43 · Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2024-03-13 | 4 | Verastem, Inc. (VSTM) | Disposition to issuer (D): 2,083 (derivative) · Disposition to issuer (D): 1,497 (derivative) · Disposition to issuer (D): 2,083 (derivative) · Disposition to issuer (D): 2,083 (derivative) · Disposition to issuer (D): 2,083 (derivative) · Disposition to issuer (D): 2,083 (derivative) · +3 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1364719 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →